Teng M, Choy H, Ettinger D
Division of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Oncology (Williston Park). 1999 Oct;13(10 Suppl 5):107-15.
After nearly 4 decades of use in treating small-cell lung cancer (SCLC), thoracic radiation has become integral to the management of limited-stage disease. Many prospective randomized trials have demonstrated that adding thoracic radiation therapy to chemotherapy improves locoregional control and survival at 3 and 5 years. This has resulted in a greater appreciation of the role of thoracic radiation in the treatment of SCLC. Currently, the most commonly used regimens incorporate concurrent administration of cisplatin (Platinol) and etoposide (VePesid) chemotherapy and radiation doses of 45 Gy given over 5 weeks. However, issues concerning timing, volume, and dose fractionation remain to be resolved.
在用于治疗小细胞肺癌（SCLC）近40年后，胸部放疗已成为局限期疾病管理中不可或缺的一部分。许多前瞻性随机试验表明，在化疗中加入胸部放疗可改善局部区域控制，并提高3年和5年生存率。这使得人们对胸部放疗在SCLC治疗中的作用有了更深刻的认识。目前，最常用的方案是顺铂（铂尔定）和依托泊苷（足叶乙苷）化疗与5周内给予45 Gy放疗剂量同时进行。然而，关于放疗时机、照射体积和剂量分割的问题仍有待解决。
